vol.2 no.1

Life Sciences Discovery Fund Update

The Life Sciences Discovery Fund has embarked on a journey of scientific progress and promise. There has been very strong interest in the Fund and its activities. With approximately $1 million from Washington State operations dollars, nearly $6 million in private donor monies and $32 million from the tobacco settlement agreement, the Fund continues to attract diverse civic support from across the State. The organizational development of the Life Sciences Discovery Fund has steadily evolved since its inception — read on about the Fund's grant competitions, award portfolio, and anticipated pathways to impact.

Grant Competitions Designed and Launched

- Four grant competitions are complete
- Very strong statewide interest: 265 proposals submitted to date
- Three-fourths of proposals received have multi-institutional partnerships
- One-half of proposals received have corporate partnerships
- 9 Washington counties represented in pool of proposal submissions
- Scientific review by national experts

21 Innovative Awards

- Totaling more than $50 million
- 9 different lead institutions, each collaborating with at least one other organization
- One-third have Eastern-Western Washington collaborations
- Research foci:
  - Autoimmune diseases (lupus, MS, Type 1 diabetes)
  - Cancer (B cell lymphoma, breast, prostate, solid tumors)
  - Cardiovascular disease (heart attack, tissue calcification)
  - Early learning
  - Independent living
  - Liver fibrosis (proteomics platform)
  - Medical genetics/genomics
  - Medication management
  - Neurological disorders (epilepsy, stroke, traumatic brain injury)
  - Pain localization
  - Surgical best practices
  - Vaccines for infectious diseases
  - Lung disease injuries
  - Drug delivery within human cells
  - Addiction
  - Rural mental health
  - Sudden cardiac arrest
- Areas of disease care — each of the 21 awards touch upon at least one aspect along the disease care continuum:
  - Prevention
  - Screening
  - Diagnosis
  - Treatment
  - Systems
  - Palliative or end-of-life care/recovery

On Track for Impact

- Potential economic impact of 21 awards:
  - 21 with potential for commercial product development or company formation
  - 3 with potential health-care cost-savings or increases in cost-effectiveness
  - 9 with potential for infrastructure and resource development
  - All show potential for enhancing the state's life sciences workforce
  - All show potential for attracting follow-on funding from public and private sources

Life Sciences
DISCOVERY FUND

LifeSciencesDiscoveryFund.org

- Examples of statewide impact:

Diabetes Evaluation in Washington State
Pacific Northwest Diabetes Research Institute



Anticipated Impact: Reduction in costs and crises for individuals and families living with Type 1 diabetes

Surgical Care and Outcomes Assessment Program
University of Washington

Anticipated Impact: Widespread adoption of best surgical practices to prevent unnecessary procedures and mistakes

Program for Autoimmune Disease Intervention
Benaroya Research Institute at Virginia Mason

Anticipated Impact: Improved targeted therapies for treatment of autoimmune diseases

- Examples of public-private enterprise through collaboration:

Existing private companies
Swedish Neuroscience Institute neurosurgeons lead by Dr. David Newell, are working with EKOS, a Bothell, Washington-based biomedical company, to provide stroke victims with a potentially superior treatment to reduce associated health problems and disabilities using a combination of ultrasound-enhanced drug delivery and advanced imaging.

Potential for start-up firms
The University of Washington's Dr. Pierre Mourad is testing an ultrasound device for its ability to localize deep pain. The value added to the technology through the Life Sciences Discovery Fund's grant award will hopefully increase the competitiveness of the start-up company, PhysioSonics, for SBIR and investment funding.

Engagement of larger corporations
Life Sciences Discovery Fund awards can enhance infrastructure development for commercialization of promising new technologies. This creates a research capacity that can be utilized by multiple projects, including those involving corporate entities. One such Fund award is the phase 1 clinical trial unit at the Fred Hutchinson Cancer Research Center. It will provide an essential capability for early human drug trials with the power to facilitate commercialization of academic discoveries and to assist local companies developing new anti-cancer agents.

These examples highlight the Fund's role in stimulating innovation to improve health for Washingtonians, generate economic vitality in the state, and keep Washington's life sciences sector vibrant. Continue to follow along in support of the Life Sciences Discovery Fund as its story unfolds.